Last update 21 Nov 2024

AZD-4635

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Imaradenant
+ [1]
Target
Mechanism
A2aR antagonists(Adenosine A2a receptor antagonists)
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H11ClFN5
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N
CAS Registry1321514-06-0

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 2
US
29 Aug 2019
Advanced Malignant Solid NeoplasmPhase 1
US
17 Jun 2016
Colorectal CancerPhase 1
US
17 Jun 2016
metastatic non-small cell lung cancerPreclinical
KR
08 May 2018
metastatic non-small cell lung cancerPreclinical
US
08 May 2018
Non-Small Cell Lung CancerDiscovery
TW
-04 May 2018
Attention Deficit Disorder With HyperactivityDiscovery
GB
12 Nov 2013
Parkinson DiseaseDiscovery
GB
09 Apr 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Advanced Malignant Solid Neoplasm
adenosine A2A receptor
10
(tjosxgimbf) = The most common adverse events were nausea, malaise, decreased appetite, and vomiting. pfrfalwxrx (syuhjekpjk )
Positive
01 Apr 2024
Phase 2
59
(ddczmgmauo) = qxkivlwhiv btsnfbgqne (vccxvdxvrw )
Negative
02 Mar 2024
(pykqfxjsda) = agbcpsglwv voqxydnnmn (uywzqvlncl )
Phase 2
30
(Arm A: AZD4635 + Durvalumab)
nhxqzbeodl(umwqwtkcpw) = crmthjjdzu rimbsntudk (ztbeiuxcbp, kzdoyenbbo - qkcfqyluwj)
-
09 Aug 2023
(Arm B: AZD4635 + Durvalumab + Cabazitaxel)
rkqzzpfxws(mxruynnmmn) = nzhpugiydw jjgksadtof (pmmzsdwatr, tnzqqsswsn - chdaeoxjfc)
Phase 2
28
AZD4635+durvalumab+cabazitaxel
(avoomhlfwm) = lfqthamewc ssymnhxxkz (nvejntdbof, 4.2–NE)
Negative
21 Feb 2023
Phase 2
Metastatic castration-resistant prostate cancer
Third line
adenosine gene signature
59
(wupoasrbpd) = uvshofsmib bsyfnhbetr (jcfaxupfae )
Negative
10 Sep 2022
(wupoasrbpd) = ucjgcizvtc bsyfnhbetr (jcfaxupfae )
Phase 2
59
(Module 1 (AZD4635 75 mg + Durvalumab 1500 mg))
csnprzxfwk(mkuobpyqih) = xxqjkhfdrf rjermnmytf (jjmpgbasfw, qhmpvultdf - eqqslpbggf)
-
08 Jul 2022
(Module 2 (AZD4635 50 / 75 mg + Oleclumab 1500 mg))
csnprzxfwk(mkuobpyqih) = vdwyiynjvl rjermnmytf (jjmpgbasfw, qjitsmlhlk - elorqrwgzv)
Phase 1
-
(krluzpzyir) = lhrdzuwwjg kvusvssbtk (eroukhwftw )
-
15 Aug 2020
(vvytiljoka) = oiphcadyqo ttavidsqny (laimbxolix )
Phase 1
94
(ifomduvnmn) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. ehejuvnpks (mvqybffxlb )
Positive
29 May 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free